Founded in 2019, Sirius Medtech, a medical device firm, will accelerate its R&D progress in the interventional treatment of pulmonary embolism and congestive heart failure.
Sirius Medtech (Chinese: 启晨医疗) completed the Pre-Series A financing round worth tens of millions of CNY, led by CDBI Partners (Chinese: 辰德资本), followed by RAYS Venture Capital (Chinese:荣安创投). The funds will be used for clinical trials and new product R&D.
Sirius Medtech is a high-tech enterprise focusing on the interventional treatment of pulmonary embolism and congestive heart failure.
The company initiated the clinical trial of TwiFlow™ on May 14, a transcatheter pulmonary artery thrombectomy system for the removal of fresh, soft emboli and thrombi from the pulmonary artery and peripheral vasculature of a patient with acute pulmonary embolism. The surgery was done by Wang Yan, the Dean of Cardiovascular Hospital Affiliated of Xiamen University.
As an emerging medical device for the treatment of heart failure, SIRIUS AFR atrial shunt system has a multi-layer braided structure using the compression technique. The first human implantation of the SIRIUS AFR was completed by the same team on November 5, 2021.
The rapid increase in the number of heart failure and pulmonary embolism patients is a global health problem. And the interventional therapy for both diseases is a market with great potential.